Ernexa Therapeutics Appoints Accomplished Biopharmaceutical Executive Robert J. Spiegel, M.D., FACP, to Board of Directors
Ernexa Therapeutics Inc ERNA
$3.45
▼ -4.83%
($-0.18)
⬇️ Below Yest. Low
🎈 Low Float
🎢 High Beta
Open
$3.73
Prev Close
$3.62
Day Range
$3.40 – $3.85
52W Range
$3.18 – $71.50
Market Cap
$5.62M
Beta
2.69
EPS (TTM)
$-25.77
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 1991-08-29 |
| Shares Out. | 1,170,000 |
| Website | ernexatx.com/ ↗ |
| Phone | 16177986700 |
| Employees | 5 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$4.0M |
| Free Cash Flow | -$8.9M |
| Total Assets | $6.3M |
| Total Liabilities | $3.1M |
| Equity | $3.2M |
About Ernexa Therapeutics Inc
Ernexa Therapeutics Inc is a preclinical-stage synthetic allogeneic iMSC therapy company developing medicines to treat various forms of cancer and other diseases with high unmet medical needs. Its main product candidate, ERNA-101, capitalizes on the intrinsic tumor-homing ability of MSCs (mesenchymal stem cells) to slip through the tumor's defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment. The firm's initial focus is to develop ERNA-101 in platinum-resistant ovarian cancer. Through another product candidate, ERNA-201, it is investigating anti-inflammatory cytokine (IL-10) secreting iMSCs in autoimmune disorders like rheumatoid arthritis. The company operates in a single reportable segment, the research and development of cellular therapies.
Ernexa Therapeutics Inc is a publicly traded company under the ticker symbol ERNA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
7 analysts (2026-09-01)